

New Journal of Chemistry

Supplementary data

Synergistic promotion of Ag nanoparticles supported on magnetic Cu based metal organic framework for A³-coupling and synthesis of benzopyranopyrimidines

Sukanya Sharma, Shally Sharma, Nitika Sharma, Vrinda Sharma and Satya Paul*

Department of Chemistry, University of Jammu, Jammu 180006, India.; Email:

satyapaul@jammuuniversity.ac.in.


List of contents

Page No.

S1. Spectral data of synthesized compounds listed in Table 4.	2-4
S2. Spectral data of synthesized compounds listed in Table 7.	4-7
S3. ¹ H and ¹³ C NMR spectra of compounds listed in Table 4.	8-23
S4. ¹ H and ¹³ C NMR spectra of compounds listed in Table 7.	24-37


S1. Spectral data of the synthesized products 4(a-h)

1-(1,3-Diphenylprop-2-ynyl)piperidine (4a)




¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, *J* = 7.5 Hz, 2H, ArH), 7.56-7.53 (m, 2H, ArH), 7.40-7.30 (m, 6H, ArH), 4.84 (s, 1H, CH), 2.60 (br, 4H, 2CH₂), 1.68-1.57 (m, 4H, 2CH₂), 1.48-1.45 (m, 2H, CH₂); **¹³C NMR (100 MHz, CDCl₃):** δ 138.40, 131.82, 128.62, 128.29, 128.08, 127.52, 123.30, 87.85, 86.00, 62.35, 50.61, 26.10, 24.40.

1-(3-Phenyl-1-p-tolylprop-2-ynyl)piperidine (4b)




¹H NMR (400 MHz, CDCl₃): δ 7.54-7.52 (m, 4H, ArH), 7.35-7.33 (m, 3H, ArH), 7.19 (d, *J* = 7.9 Hz, 2H, ArH), 4.79 (s, 1H, CH), 2.58 (t, *J* = 4.6 Hz, 4H, 2CH₂), 2.38 (s, 3H, CH₃), 1.63-1.59 (m, 4H, 2CH₂), 1.47-1.44 (m, 2H, CH₂); **¹³C NMR (100 MHz, CDCl₃):** δ 137.18, 135.48, 131.80, 128.77, 128.55, 128.26, 127.97, 123.37, 87.63, 86.28, 62.06, 50.62, 26.09, 24.41, 21.13.

1-(3-Phenyl-1-m-tolylprop-2-ynyl)piperidine (4c)




¹H NMR (400 MHz, CDCl₃): δ 7.56-7.52 (m, 2H), 7.45 (d, *J* = 1.7 Hz, 2H), 7.38-7.34 (m, 3H), 7.26 (d, *J* = 7.9 Hz, 1H), 7.13 (d, *J* = 7.5 Hz, 1H), 4.77 (s, 1H), 2.60-2.58 (m, 4H), 2.40 (s, 3H), 1.67-1.56 (m, 4H), 1.47 (dt, *J* = 8.8, 4.6 Hz, 2H); **¹³C NMR (100 MHz, CDCl₃):** δ 138.29, 137.70, 131.82, 129.29, 128.45, 128.27, 128.05, 127.95, 125.74, 123.36, 87.73, 86.21, 62.41, 50.78, 26.09, 24.40, 21.54.

1-(4-Methoxyphenyl)-3-phenylprop-2-ynyl)piperidine (4d)




$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.60-7.56 (m, 4H, ArH), 7.39-7.35 (m, 3H, ArH), 6.94 (d, $J = 8.6$ Hz, 2H, ArH), 4.79 (s, 1H, CH), 3.84 (s, 3H, OCH_3), 2.60 (br, 4H, 2CH_2), 1.69-1.58 (m, 4H, 2CH_2), 1.50-1.47 (m, 2H, CH_2); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 159.02, 131.83, 130.73, 129.69, 128.31, 128.05, 123.43, 113.42, 87.67, 86.47, 61.82, 55.27, 50.64, 26.23, 24.54.

1-(4-Bromophenyl)-3-phenylprop-2-ynyl)piperidine (4e)




$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.57-7.50 (m, 6H, ArH), 7.37-7.36 (m, 3H, ArH), 4.78 (s, 1H, CH), 2.57 (br, 4H, 2CH_2), 1.68-1.56 (m, 4H, 2CH_2), 1.49-1.48 (m, 2H, CH_2); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 137.81, 131.83, 131.18, 130.23, 128.35, 128.25, 123.07, 121.41, 88.29, 85.28, 61.78, 50.71, 26.15, 24.38.

1-(4-Chlorophenyl)-3-phenylprop-2-ynyl)piperidine (4f)




$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.61 (d, $J = 8.4$ Hz, 2H, ArH), 7.55-7.53 (m, 2H, ArH), 7.37-7.34 (m, 5H, ArH), 4.79 (s, 1H, CH), 2.56 (t, $J = 4.7$ Hz, 4H, 2CH_2), 1.65-1.58 (m, 4H, 2CH_2), 1.48-1.45 (m, 2H, CH_2); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 137.32, 133.19, 131.82, 130.93, 129.83, 128.33, 128.20, 123.10, 88.24, 85.39, 61.73, 50.73, 26.16, 24.39.

4-(1,3-Diphenylprop-2-ynyl)morpholine (4g)



¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, *J* = 7.3 Hz, 2H, ArH), 7.58-7.55 (m, 2H, ArH), 7.43-7.33 (m, 6H, ArH), 4.84 (s, 1H, CH), 3.82-3.73 (m, 4H, 2CH₂), 2.68 (br, 4H, 2CH₂); **¹³C NMR (100 MHz, CDCl₃):** δ 137.84, 131.85, 128.63, 128.36, 128.30, 128.27, 127.82, 123.01, 88.53, 85.08, 67.20, 62.07, 49.91.


4-(1-(4-bromophenyl)-3-phenylprop-2-ynyl)morpholine (4h)



¹H NMR (400 MHz, CDCl₃): δ 7.56-7.50 (m, 6H), 7.38-7.35 (m, 3H), 4.77 (s, 1H), 3.80-3.71 (m, 4H), 2.64 (t, *J* = 4.4 Hz, 4H); **¹³C NMR (100 MHz, CDCl₃):** δ 136.96, 131.81, 131.35, 130.26, 128.44, 128.37, 122.67, 121.75, 88.93, 84.23, 67.11, 61.42, 49.77.

S2. Spectral data of the synthesized products 8(a-g)


2-(4-(piperidin-1-yl)-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8a)



¹H NMR (400 MHz, CDCl₃): δ 13.49 (brs, 1H, OH), 8.45 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.40-7.35 (m, 1H, Ar), 7.23 (dd, *J* = 8.9, 8.0 Hz, 3H, Ar), 7.15-7.13 (m, 1H, Ar), 7.00 (d, 1H, *J* = 8 Hz, Ar), 6.96-6.92 (m, 1H), 3.95 (s, 2H, CH₂), 3.48-3.45 [m, 4H, N(CH₂)₂], 1.81-1.76 (m, 6H, 3CH₂); **¹³C**


NMR (100 MHz, CDCl₃): δ 165.38, 164.50, 162.08, 160.44, 150.71, 132.84, 129.22, 128.54, 128.22, 124.40, 119.59, 118.84, 118.61, 117.55, 117.13, 97.62, 49.55, 25.99, 25.65, 24.36.

2-(4-morpholino-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8b)




¹H NMR (400 MHz, CDCl₃): δ 13.12 (brs, 1H, OH), 8.39 (d, J = 7.9 Hz, 1H, Ar), 7.35 (t, J = 7.7 Hz, 1H, Ar), 7.25-7.17 (m, 3H, Ar), 7.11 (t, J = 7.2 Hz, 1H, Ar), 6.97 (d, J = 8.2 Hz, 1H, Ar), 6.91 (t, J = 6.8 Hz, 1H, Ar), 3.93-3.90 (m, 6H), 3.50 (s, 4H, 2CH₂); **¹³C NMR (100 MHz, CDCl₃):** δ 164.84, 164.34, 162.16, 160.34, 150.42, 133.01, 129.19, 128.57, 128.37, 124.63, 119.09, 118.93, 118.43, 117.62, 117.11, 97.83, 66.74, 48.67, 25.93.

4-bromo-2-(7-bromo-4-piperidin-1-yl)-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8c)




¹H NMR (400 MHz, CDCl₃): δ 13.39 (brs, 1H, OH), 8.52 (d, J = 8.0 Hz, 1H, Ar), 7.43 (dd, J = 8.7, 2.5 Hz, 1H, Ar), 7.38 (d, J = 8.1 Hz, 2H, Ar), 7.10 (d, J = 8.3 Hz, 1H, Ar), 6.88 (d, J = 8.7 Hz, 1H, Ar), 3.92 (s, 2H), 3.46 (t, J = 13.9 Hz, 4H), 1.78 (s, 6H); **¹³C NMR (100 MHz, CDCl₃):** δ 165.18, 164.07, 160.97, 159.50, 149.73, 135.55, 131.33, 131.30, 131.26, 121.59, 120.08, 119.55, 118.92, 116.95, 111.02, 97.25, 49.54, 25.91, 25.50, 24.27.

4-bromo-2-(7-bromo-4-morpholino-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8d)




¹H NMR (400 MHz, CDCl₃): δ 13.03 (brs, 1H, OH), 8.46 (d, J = 7.9 Hz, 1H, Ar), 7.43-7.37 (m, 3H, Ar), 7.07 (d, J = 8.3 Hz, 1H, Ar), 6.85 (d, J = 8.8 Hz, 1H, Ar), 3.94-3.89 (m, 6H), 3.51 (t, J = 4 Hz, 2H, CH₂); **¹³C NMR (100 MHz, CDCl₃):** δ 164.80, 163.66, 161.06, 159.43, 149.35, 135.72, 131.94, 131.47, 131.38, 131.30, 121.02, 119.66, 118.82, 117.08, 110.96, 97.51, 66.74, 48.65, 25.26.

4-bromo-2-(7-bromo-4-(pyrrolidin-1-yl)-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8e)




¹H NMR (400 MHz, CDCl₃): δ 13.64 (brs, 1H, OH), 8.52 (d, J = 8.0 Hz, 1H, Ar), 7.42 (dd, J = 8.7, 2.2 Hz, 1H, Ar), 7.36 (d, J = 9.0 Hz, 1H, Ar), 7.33 (s, 1H, Ar), 7.07 (d, J = 8.6 Hz, 1H, Ar), 6.86 (d, J = 8.7 Hz, 1H, Ar), 4.26 (s, 2H, CH₂), 3.84 (t, J = 6.0 Hz, 4H), 1.28 (t, J = 7.1 Hz, 4H); **¹³C NMR (100 MHz, CDCl₃):** δ 161.24, 160.80, 160.32, 159.57, 149.27, 135.34, 131.34, 131.30, 130.87, 121.25, 120.14, 119.43, 118.76, 116.54, 110.88, 91.44, 60.73, 50.01, 25.63.

4-nitro-2-(7-nitro-4-morpholino-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8f)




¹H NMR (400 MHz, CDCl₃): δ 13.82 (brs, 1H, OH), 9.32 (d, *J* = 8.0 Hz, 1H, Ar), 8.28 (dd, *J* = 9.2, 2.8 Hz, 1H), 8.23 (d, *J* = 7.6 Hz, 2H), 7.36 (d, *J* = 9.8 Hz, 1H), 7.15-7.12 (m, 1H), 4.11 (s, 2H), 3.97 (t, *J* = 4 Hz, 4H), 3.63 (s, 4H); **¹³C NMR (100 MHz, CDCl₃):** δ 165.99, 156.64, 155.31, 155.13, 154.77, 144.48, 140.32, 128.45, 128.33, 125.89, 124.69, 124.61, 120.13, 118.73, 118.14, 105.46, 66.76, 48.67, 25.93.

4-nitro-2-(7-nitro-4-(pyrrolidin-1-yl)-5H-chromeno[2,3-d]pyrimidin-2-yl)phenol (8g)




¹H NMR (400 MHz, CDCl₃): δ 14.43 (brs, 1H, OH), 9.33 (s, 1H, Ar), 8.25 (d, *J* = 7.8 Hz, 1H, Ar), 8.20-8.16 (m, 2H, Ar), 6.93 (d, *J* = 8 Hz, 1H, Ar), 7.05 (d, *J* = 9.1 Hz, 1H), 4.42 (s, 2H), 3.92 (s, 4H), 1.28 (s, 4H); **¹³C NMR (100 MHz, CDCl₃):** δ 166.01, 157.08, 155.86, 155.64, 153.51, 142.26, 140.31, 127.92, 125.81, 124.77, 124.43, 118.41, 117.87, 111.63, 60.71, 50.33, 25.64.


S3. ^1H and ^{13}C NMR spectra of compounds listed in Table 4.




^1H NMR spectra of product (4a)




¹³C NMR spectra of product (4a)



¹H NMR spectra of product (4b)




¹³C NMR spectra of product (4b)




Parameter	Value
1 Data File Name	C:/Users/sukanya sharma/Desktop/38/ fid
2 Title	38
3 Comment	MME
4 Origin	Bruker BioSpin GmbH
5 Owner	nmsu
6 Site	
7 Spectrometer	spect
8 Author	
9 Solvent	CDCl3
10 Temperature	0.0
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	199
14 Relaxation Delay	1.0000
15 Pulse Width	15.0000
16 Acquisition Time	4.0894
17 Acquisition Date	2022-10-16T13:49:56
18 Modification Date	2022-10-22T17:00:55
19 Spectrometer Frequency	400.13
20 Spectral Width	8012.8
21 Lowest Frequency	-1535.6
22 Nucleus	^1H
23 Acquired Size	32768
24 Spectral Size	65536


^1H NMR spectra of product (4c)




¹³C NMR spectra of product (4c)




¹H NMR spectra of product (4d)




¹³C NMR spectra of product (4d)




¹H NMR spectra of product (4e)




¹³C NMR spectra of product (4e)




¹H NMR spectra of product (4f)




¹³C NMR spectra of product (4f)




^1H NMR spectra of product (4g)



¹³C NMR spectra of product (4g)




¹H NMR spectra of product (4h)




¹³C NMR spectra of product (4h)


S4. ¹H and ¹³C NMR spectra of compounds listed in Table 7




¹H NMR spectra of product (8a)




¹³C NMR spectra of product (8a)




¹H NMR spectra of product (8b)




¹³C NMR spectra of product (8b)




¹H NMR spectra of product (8c)




¹³C NMR spectra of product (8c)




¹H NMR spectra of product (8d)




¹³C NMR spectra of product (8d)




¹H NMR spectra of product (8e)




¹³C NMR spectra of product (8e)




¹H NMR spectra of product (8f)



¹³C NMR spectra of product (8f)



¹H NMR spectra of product (8g)



¹³C NMR spectra of product (8g)